Pravastatin for the prevention of preeclampsia in high-risk pregnant women

Obstetrics and Gynecology

Volumn 121, Issue 2 PART 1, 2013, Pages 349-353

  Costantine, Maged M ^a,b   Cleary, Kirsten ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; C REACTIVE PROTEIN; CALCIUM; FISH OIL; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; CHOLESTEROL SYNTHESIS; CONGENITAL MALFORMATION; CYTOKINE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; ENDOTHELIUM INJURY; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; OXIDATIVE STRESS; PATHOGENESIS; POSTMARKETING SURVEILLANCE; PREECLAMPSIA; PREGNANCY OUTCOME; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SUPPLEMENTATION; TERATOGENICITY;

CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PRAVASTATIN; PRE-ECLAMPSIA; PREGNANCY; RISK FACTORS;

EID: 84873828168     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31827d8ad5     Document Type: Review

References (31)

1. Santillan MK, Santillan DA, Sigmund CD, Hunter SK. From molecules to medicine: a future cure for preeclampsia. Drug News Perspect 2009;22:531-41.
2. Van Pampus MG, Aarnoudse JG. Long term outcomes after preeclmapsia. Clin Obstet Gynecol 2005;48:489-94.
3. Barton JR, Sibai B. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 2008;112:359.
4. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol 2010;5:173-92.
5. Roberts JM, Cooper DW. Pathogenesis genetics of pre-eclampsia. Lancet 2001;357:53-6.
6. RammaW, Ahmed A. Is inflammation the cause of preeclampsia? Biochem Soc Trans 2011;39:1619-27.
7. Branch DW, Mitchell MD, Miller E, Palinski W, Witztum JL. Pre-eclampsia and serum antibodies to oxidized low-density lipoprotein. Lancet 1994;343:645-6.
8. Ahmed A, Cudmore MJ. Can the biology of VEGF and heme oxygenases help solve preeclampsia? Biochem Soc Trans 2009; 37:1237-42.
9. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005;352:1685-95.
10. McDonald SD, Malinowski A, Zhou Q, Yusuf S, Devereaux PJ. Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. Am Heart J 2008;156:918-30.
11. Mongraw-Chaffin ML, Cirillo PM, Cohn BA. Preeclampsia and cardiovascular disease death: prospective evidence from the child health and development studies cohort. Hypertension. 2010;56:166-71.
12. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2007;1: CD002252.
13. Levine RJ, Hauth JC, Curet LB, et al. Trial of calcium to prevent preeclampsia. N Engl J Med 1997;337:69-76.
14. Conde-Agudelo A, Romnero R, Kusanovic JP, Hassan SS. Supplementation with vitamins C and E during pregnancy for the prevention of preeclampsia and other adverse maternal and perinatal outcomes: a systematic review and metaanalysis. Am J Obstet Gynecol 2011;204:503.e1-12.
15. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA; PARIS Collaborative Group. Antiplatelet agents for prevention of preeclampsia: a meta-analysis of individual patient data. Lancet 2007;369:1791-8.
16. Bujold E, Roberge S, Lacasse Y. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy. A meta-analysis. Obstet Gynecol 2010;116:402-14.
17. Costantine M, Tamayo E, Bytautiene E, et al. Using pravastatin to improve the vascular reactivity in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol 2010;116:114-20.
18. Fox KA, Longo M, Tamayo E, et al. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol 2011;205:366.e1-5.
19. Ahmed A, Singh J, Khan Y, Seshan SV, Girardi G. A new mouse model to explore therapies for preeclampsia. PLoS One 2010;5:e13663.
20. Singh J, Ahmed A, Girardi G. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 2011; 58:716-24.
21. Kumasawa K, Ikawa M, Kidoya H, et al. Pravastatin induces placental growth factor and ameliorates preeclampsia in a mouse model. PNAS 2011;108:1451-5.
22. Ridker PM, Danielson E, Fonseca FA, et al JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207.
23. Greenwood J, Steinman L, Zamivil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006;6:358-70.
24. U.S Food and Drug Administration. Drug bulletin. Fed Reg 1980;44:37434-67.
25. Kazmin A, Garcia-Bournissen F, Koren G. Risk of statin use during pregnancy: a systematic review. J Obstet Gynaecol Can 2007;29:906.
26. Edison R, Muenke M. Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins. Am J Med Gen 2004;131A:287.
27. Ofori B, Rey E, Berard A. Risk of congenital anomalies in pregnant users of statin drugs. Br J Clin Pharmacol 2007;64: 496.
28. Taguchi N, Rubin ET, Hosokawa A. Prenatal exposure to HMG-CoA reductase inhibitor: effects on fetal and neonatal outcomes. Reprod Toxicol 2008;26:175.
29. Petersen EE, Mitchell AA, Carey JC, Werler MM, Louik C, Rasmussen SA, et al. Maternal exposure to statins and risk for birth defects. Am J Med Genet A 2008;146A:2701-5.
30. Hatanaka T. Clinical pharmacokinetics pravastatin. Clin Pharmacokinet 2000;39:397-412.
31. Kane AD, Herrera EA, Hansell JA, Giussani DA. Statin treatment depresses the fetal defence to acute hypoxia via increasing nitric oxide bioavailability. J Physiol 2012;590: 323-34.